APA (7th ed.) Citation

Y, H., Q, G., H, C., T, Q., X, Z., Q, D., . . . S, Z. (2026). Site-specific trastuzumab Fab-DM1 via butelase-1 with ABD fusion for potent HER2-positive tumor control. Medical oncology (Northwood, London, England), 43(8), . https://doi.org/10.1007/s12032-026-03317-3

Chicago Style (17th ed.) Citation

Y, Han, et al. "Site-specific Trastuzumab Fab-DM1 via Butelase-1 with ABD Fusion for Potent HER2-positive Tumor Control." Medical Oncology (Northwood, London, England) 43, no. 8 (2026). https://doi.org/10.1007/s12032-026-03317-3.

MLA (9th ed.) Citation

Y, Han, et al. "Site-specific Trastuzumab Fab-DM1 via Butelase-1 with ABD Fusion for Potent HER2-positive Tumor Control." Medical Oncology (Northwood, London, England), vol. 43, no. 8, 2026, https://doi.org/10.1007/s12032-026-03317-3.